CrushSCI.com
220.7Average days
195Median days
15Fastest days
428Longest days
952025 publications

Paper Review Records

All Paper Review Records

19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

195 days

Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database

Authors
Davide Rozza; Elisabetta Poluzzi; Ippazio Cosimo Antonazzo; Angela Boccia; Marco Paccini; Fortuna Gallucci; Domenico Ponticelli; Giulio Geraci; Fernando Agüero; Giampiero Mazzaglia; Lorenzo Giovanni Mantovani; Emanuel Raschi; Pietro FerraraShow moreShow less
Affiliations
1. Center for Public Health Research, University of Milan–Bicocca, Monza, Italy; 2. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 3. Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy; 4. Clinica Montevergine SpA, Mercogliano, Italy; 5. Department of Medicine and Surgery, “Kore” University of Enna, Enna, Italy; 6. Internal Medicine Unit, Hospital Umberto I, ASP Enna, Enna, Italy; 7. Preventive Medicine Unit, Hospital Universitari General de Catalunya, Quirónsalud, Barcelona, Spain; 8. Laboratory of Public Health, IRCCS Istituto Auxologico Italiano, Milan, ItalyShow moreShow less
Source PDF DOI Publisher page
258 days

Statin Use and Arterial Calcification in the General Population: A Longitudinal Analysis and a Negative Control Population

Authors
Mitra Nekouei Shahraki; Jeremy A Labrecque; Fariba Ahmadizar; Bruno H Stricker; Maryam Kavousi; Daniel BosShow moreShow less
Affiliations
1. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Department of Data Science and Biostatistics, Julius Global Health, University Medical Center Utrecht, Utrecht, The Netherlands; 3. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The NetherlandsShow moreShow less
Source PDF DOI Publisher page
173 days

Pharmacokinetics and Tolerability of Fexinidazole in Subjects with Hepatic Impairment

Authors
Matthieu Gassiot; Jean Pierre Beaucire; Sophie Hays; Sarah Lezzar; Céline Beauchard; Eric SultanShow moreShow less
Affiliations
1. Sanofi R&D, Montpellier, France; 2. Sanofi, Gentilly, France; 3. Biotrial, Rennes, France; 4. PhinC Development, Massy, France; 5. Foundation S, The Sanofi Collective, Gentilly, FranceShow moreShow less
Source PDF DOI Publisher page
179 days

Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait

Authors
Humaid O. Al-Shamsi; Mohamed Farghaly; Ammar Abdaljalil; Abdulwahab Al-Tourah; Chana Saad; Youmna Bassil; Ghadah Albassam; Rami Nimer; Monika Naroz; Omar El-Badry; Rony AkelShow moreShow less
Affiliations
1. Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; 2. Dubai Health Insurance Corporation, Dubai, United Arab Emirates; 3. Sheikh Shakhboot Medical City, Abu Dhabi, United Arab Emirates; 4. Kuwait Cancer Control Center, Kuwait City, Kuwait; 5. Center of Clinical, Health Economics, and Outcomes Research (CCHO-FZ-LLC), Dubai, United Arab Emirates; 6. MSD KSA GmbH, Riyadh, Saudi Arabia; 7. MSD IDEA Middle East, Dubai, United Arab EmiratesShow moreShow less
Source PDF DOI Publisher page
190 days

Efficacy and Safety of Ustekinumab Biosimilars in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis

Authors
Mohsin Rashid; Awon Muhammad; Eeraj Saeed; Ali Akram Qureshi; Mohammad Maheer Mubashir; Mohammad Waqas bin Waheed; Muhammad Abdullah Yasin; Muhammad Abdullah; Ahsan Rashid; Zainab ZubairShow moreShow less
Affiliations
1. Department of Medicine, King Edward Medical University, Lahore, Pakistan; 2. Department of Medicine, District Headquarters Hospital, Jhelum, Pakistan; 3. Department of Medicine, Fatima Jinnah Medical University, Lahore, PakistanShow moreShow less
Source PDF DOI Publisher page
419 days

Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review

Authors
Mohammad Alimoradnori; Ali Abutorabi; Mozhdeh Zabihiyeganeh; Jalal Arabloo; Reza JahanghiriShow moreShow less
Affiliations
1. Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran; 2. Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran; 3. Department of Orthopedics, Bone and Joint Reconstruction Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; 4. Hospital Management Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, IranShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does CLINICAL DRUG INVESTIGATION take to review a manuscript?

As of 2026-11-19, CrushSCI has 19 complete review records for CLINICAL DRUG INVESTIGATION. The fastest paper went from submission to acceptance in 15 days (Deuruxolitinib: New Approval, received 2026-04-29, accepted 2026-05-14); the slowest took 428 days. The average is 220.7 days and the median is 195 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.